Camrelizumab-induced anaphylactic reaction: a case report and literature review.

Camrelizumab is an immune checkpoint inhibitor clinically used to treat various types of tumours. In this study, the authors provided the first report of a case of an anaphylactic reaction induced by camrelizumab in the treatment of a patient with squamous cell carcinoma of the floor of the mouth. The patient, a 58-year-old man, was diagnosed with advanced squamous cell carcinoma of the floor of the mouth, with cancer infiltration and multiple metastases. He underwent treatment for nine cycles, in which cycles 1-5 he received camrelizumab, albumin-bound paclitaxel, and cisplatin (200 mg of camrelizumab each time, every 3 weeks), with no adverse reactions; in cycle 6, he received albumin-bound paclitaxel and cisplatin, with no adverse reactions; and in cycles 7-9, he received camrelizumab and albumin-bound paclitaxel. However, 30 min after 8th administration of camrelizumab (cycle 9), he suddenly developed sweating, a pale complexion, clamminess and cyanosis of the limbs (percutaneous arterial oxygen saturation [SpO2] = 82%, blood pressure [BP] = 79/49 mmHg, heart rate [HR] = 83 beats/min [bpm] and respiratory rate [RR) = 12 bpm). The patient underwent intravenous infusion of methylprednisolone (80 mg) combined with dopamine to boost the BP; he regained consciousness 20 min later, and many parts of his skin appeared smooth, with no desquamation and accompanied by itching erythema, especially on the upper limbs. Approximately 2 h after treatment, the patient's skin erythema subsided (vital sign monitoring results: SpO2 = 100%, BP = 122/84 mmHg, HR = 91 bpm and RR = 17 bpm); the patient did not complain about his obvious discomfort. Despite the rarity of acute anaphylactic reactions among immune-related adverse reactions, great importance should be given to anaphylactic reactions of camrelizumab due to its extensive clinical application.

Thermo-sensitive amylase-starch double-layer polymer nanoparticles with self-polishing and protein corona-free property for drug delivery applications.

Protein corona formation can lead to obstructive screening of targeting groups of nanoparticles (NPs). Also, the targeting groups are subjected to physiochemical interactions when exposed to solvents. Here, these two factors can influence NP targeting efficiency. Therefore, it is necessary to prepare a general method of preparing an anti-fouling NPs with protected targeting groups. Here, we designed α-amylase-starch double-layer coated poly (methyl methacrylate-co-acrylic acid) NPs (α-ams-SCMMA NPs), functionalized with aptamer targeting groups and doped with Tetrakis(para-hydraoxylphenyl) porphyrin (TPPOH) as a payload drug. Natural polysaccharide starch and enzyme α-amylase were applied here for thermo-sensitive activation of starch hydrolyzation in order to render the NPs' self-polishing from protein corona effects. During incubation with serum media, the protein corona was formed at the exterior shell of NPs, while the self-polishing process was activated to remove the "protein fouling" when the incubation temperature increased to 37 °C (body temperature). Mechanistically, the starch layer of α-ams-SCMMA NPs was readily hydrolysed by α-amylase, whereby the adsorbed protein corona could be efficiently eliminated and the targeting groups were then presented. With this unique self-polishing NP design, we believe our method can be applied for potential NP applications in cancer therepy due to excellent antifouling property and protected targeting groups.

FGF receptor-mediated gene delivery using ligands coupled to polyethylenimine.

To obtain new nonviral vectors with high gene delivery efficiency and special cell targeting ability, an attractive strategy is to link ligands to polyethylenimine (PEI). Fibroblast growth factor receptors (FGFRs) are highly expressed on a variety of human cancer cells and are potential targets for cancer gene therapy. In this study, the peptides NH2-Met-Gln-Leu-Pro-Leu-Ala-ThrGly-Gly-Gly-Cys-COOH (MC11) which have been proved to combine specially with the FGFR on cell membrane are coupled to PEI using N-Succinimidyl-3-(2-pyridyldithio) propionate (SPDP) as a linker with different molar ratios (1 : 0.3, 1 : 0.75, 1 : 1.5, and 1 : 3.0) and the new polymer PEI-MC11 is verified by a series of physicochemical methods including 1H-NMR and FTIR. The agarose gel electrophoresis assay, particle size test, zeta potential test, and electron microscope observation show that PEI-MC11 can efficiently condense plasmid DNA into nanoparticles with about 200 nm in diameter and with positive surface charge at the suitable N/P ratio. The MTT assay suggests the decreased toxicity of the polymers. The results of the gene delivery efficiency in vitro show that PEI-MC11/pDNA polyplexes have significantly greater transgene activity than PEI/pDNA in COS-7 and HepG2 cells which express FGFR positively, while no such effect is observed in PC3 cells which have negative FGFR. The enhanced gene delivery efficiency of PEI-MC11 can be blocked by the co-culture of free peptides MC11 before the gene delivery procedure. The synthesized nonviral vector based on PEI with the targeting peptides MC11 for binding FGFR has improved efficiency of gene delivery and targeting specificity in FGFR positive cells. It may have potential application in cancer gene therapy.

Protonation effect on ligands in EuL: a luminescent switcher for fast naked-eye detection of HCl.

A new luminescent coordination polymer, EuH(L)(2)(NO(3))(2) (EuL, HL = 2-(2-pyridin-2-yl)quinoline-4-carboxylic acid), has been solvothermally synthesized, and its framework of uncoordinated pyridyl rings was exploited for the binding and specific sensing of HCl via a protonation effect. The protonation effect changes the energy of the excited state of the ligands, rendering them unable to act as efficient antennae for Eu(3+) characteristic emission. Thus, we have developed a new, fast and convenient sensor for HCl, a gas harmful for the environment.